News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

6

ATEC Reports First Quarter Financial Results and Recent Corporate Highlights

US Revenue Growth Accelerates to 50%; Revenue Growth Averages~33% Over Past Eight Quarters CARLSBAD,...

6

electroCore Announces First Quarter 2021 Financial Results

Record first quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020...

4

Exagen Inc., Allegheny Health Network Research Institute, and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis,...

4

electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache

Randomized, multi-center, double-blind, parallel, sham-controlled trial enrolling up to 100 veterans and directed by...

3

Exagen Announces New Campaign and Initiatives for Lupus Awareness Month

Joint effort with the Lupus Foundation of America and LupusChick SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE)...

26

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

Economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled...

20

electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar

Introduction of nVNS therapy, gammaCore Sapphire, in the Middle East ROCKAWAY, NJ, April 20, 2021 (GLOBE...

15

electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache

gammaCore identified as the only therapy that shown to be effective in clinical trials...

14

TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists

Regional Delivery of Oligodeoxynucleotides (ODN2395) Showed Activation of Toll-Like Receptor Agonist in Mice Ineffective...

13

electroCore Provides Business Update and Select First Quarter 2021 Financial Guidance

First-quarter 2021 revenue expected to be more than $1.1 million Net cash used for the...

8

TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors

Studies to evaluate liver and pancreatic cancers with SD-101, an investigational TLR9 agonist, in...

8

ATEC Announces Preliminary First Quarter 2021 Revenue Results and Provides Corporate Updates

First quarter 2021 U.S. revenue grows approximately 50% compared to last year Full-year 2021...